Real Time Touch



new TOP 200 Companies filing patents this week

new Companies with the Most Patent Filings (2010+)




Real Time Touch

Similar
Filing Names

Ucl Business Plc
Ucl Business Plc The Network Building

Ucl Business Plc patents


Recent patent applications related to Ucl Business Plc. Ucl Business Plc is listed as an Agent/Assignee. Note: Ucl Business Plc may have other listings under different names/spellings. We're not affiliated with Ucl Business Plc, we're just tracking patents.

ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 | Company Directory "U" | Ucl Business Plc-related inventors


 new patent  Blood filter

A blood filter device having an iron-chelating molecule, a haem-binding molecule and a haemoglobin-binding molecule bound to a support. Use of the device in a vessel containing blood, for example a blood bag or a flow line, removes haemolysis-derived components from the blood.... Ucl Business Plc

 new patent  Signalling system

The present invention relates to a chimeric antigen-receptor (CAR) signalling system comprising; (i) a targeting component comprising an antigen-binding domain, a transmembrane domain and a first heterodimerization domain; and (ii) an intracellular signalling component comprising a signalling domain and a second heterodimerization domain; wherein spontaneous heterodimerization between the first and... Ucl Business Plc

Optimised coding sequence and promoter

An optimized coding sequence of human blood clotting factor eight (VIII) and a promoter may be used in vectors, such as rAAV, for introduction of factor VIII, and/or other blood clotting factors and transgenes. Exemplary of these factors and transgenes arc alpha-1-antitrypsin, as well as those involved in the coagulation... Ucl Business Plc

Cell

The present invention provides a cell which co-expresses a first chimeric antigen receptor (CAR) and second CAR at the cell surface, each CAR comprising an antigen-binding domain, wherein the antigen-binding domain of the first CAR binds to CD19 and the antigen-binding domain of the second CAR binds to CD22.... Ucl Business Plc

Treatment of diseases associated with hepatic stellate cell activation using ammonia-lowering therapies

Disclosed herein are methods of preventing, treating, and delaying the onset or progression of diseases associated with hepatic stellate cells (HSCs), such as non-alcoholic fatty liver disease (NAFLD), fibrosis, and liver cancer, using ammonia-lowering therapies.... Ucl Business Plc

Chimeric protein

The present invention provides a chimeric protein having the formula: Casp-Ht1-Ht2 wherein Casp is a caspase domain; Ht1 is a first heterodimerization domain; and Ht2 is a second heterodimerization domain and wherein, in the presence of a chemical inducer of dimerization (CID), an identical pair of the chimeric proteins interact... Ucl Business Plc

Quinolium conjugates of cyclosporin

The present invention relates to conjugates of cyclosporin with quinolium mitochondrial targeting groups, and their therapeutic uses.... Ucl Business Plc

Cell

The present invention provides a cell which co-expresses a first chimeric antigen receptor (CAR) and second CAR at the cell surface, each CAR comprising an antigen-binding domain, wherein the antigen-binding domain of the first CAR binds to CD19 and the antigen-binding domain of the second CAR binds to CD22.... Ucl Business Plc

Cell

The present invention provides a cell which co-expresses a first chimeric antigen receptor (CAR) and second CAR at the cell surface, each CAR comprising an antigen-binding domain, wherein the antigen-binding domain of the first CAR binds to CD19 and the antigen-binding domain of the second CAR binds to CD22.... Ucl Business Plc

Ligand

The present invention provides a variant proliferation-inducing ligand (APRIL), which has a higher binding affinity to BCMA than wild-type APRIL; and/or altered binding kinetics compared with wild-type APRIL, and/or a higher BCMA:TACI (transmembrane activator and calcium modulator and cyclophilin ligand interactor) binding ratio than wild-type APRIL and which comprises mutations... Ucl Business Plc

Chimeric antigen receptor (car) with antigen binding domains to the t cell receptor beta constant region

The present disclosure relates to a chimeric antigen receptor (CAR) which comprises an antigen-binding domain which selectively binds TCR beta constant region 1 (TRBC1) or TRBC2; cells; such a T cells comprising such a CAR; and the use of such cells for the treatment of a T-cell lymphoma or leukaemia... Ucl Business Plc

Method

The present invention provides a method for increasing the sensitivity of a T cell expressing a cell-surface antibody to a target antigen, which comprises the step of lowering the affinity of the antibody to the target antigen by at least 100-fold. The invention also provides chimeric antigen receptor comprising an... Ucl Business Plc

Device and method

A device for modulating biological tissue and/or bone conformation, the device including a shape memory material and being capable of modulating biological tissue and/or bone conformation simultaneously in at least two dimensions, a process for producing the device, a process for modulating biological tissue and/or bone using the device, and... Ucl Business Plc

Detection and treatment of breast cancer

The present invention also enables the chemosensitisation of mitotically delayed breast cancer cells to anti-proliferative agents, preferably anti-mitotic agents, by restoring normal progression through mitosis. In this embodiment a first drug is applied to release breast cancer cells from the mitotic block and, sequentially, a second drug affecting proliferating cells... Ucl Business Plc

Method and the detection of faults in data computations

A method and apparatus for detecting and mitigating faults in numerical computations of M input data streams is claimed (embodiments of FIG. 1 and FIG. 14). Such faults may occur due to circuit or processor malfunctions stemming from (but not limited to): supply voltage or current fluctuation, timing signal errors,... Ucl Business Plc

Quinolones as inhibitors of class iv bromodomain proteins

The present invention provides compounds of formula (I) as described herein and pharmaceutically acceptable salts, hydrates and solvates thereof for use in medicine, for example in the treatment of acute myeloid leukaemia:... Ucl Business Plc

Method of metallic clusters fabrication with desired size using scanning tunneling microscopy tip induced reactions

A method of transferring a single metal atom from a first location to a second location on the surface of a metal oxide is disclosed. The method includes obtaining a material having a first metal atom deposited on a first oxygen atom vacancy of the metal oxide and transferring the... Ucl Business Plc

Non-immunosuppressive cyclosporin derivatives as antiviral agents

G1 and G3 represent a hydrogen atom, a —COOR′ group, or a phenyl moiety which is unsubstituted or substituted by one, two or three substituents selected from a halogen atom, a —COOR′ group, a —CONR′R″ group, a hydroxyl group, a C1-C6 alkyl group and a C1-C6 alkoxy group, wherein R′... Ucl Business Plc

Signalling system

The present invention provides a chimeric antigen receptor (CAR) signalling system comprising; (i) a receptor component comprising an antigen binding domain, a transmembrane domain and a first binding domain; and (ii) an intracellular signalling component comprising a signalling domain and a second binding domain which specifically binds the first binding... Ucl Business Plc

Subtalar joint implant

A subtalar joint implant (20) is disclosed for replacing a natural subtalar joint existing between the talus (102) and calcaneum (104) bones of a patient. In an embodiment the implant comprises talar (22) and calcaneal (24) portions that are configured to slide over each other in the implanted state. The... Ucl Business Plc

Method and means for purifying retroviral vectors

The present invention relates to a producer cell which expresses a tagging protein at the cell surface, such that retroviral vectors produced by the cell are tagged with the tagging protein, wherein the tagging protein comprises: i) a binding domain which binds to a capture moiety ii) a spacer; and... Ucl Business Plc

Rpgr gene therapy for retinitis pigmentosa

Methods for treating a human subject who has X-linked Retinitis Pigmentosa (XLRP) or another clinically-defined ophthalmological condition due to a loss-of-function mutation in the gene encoding the retinitis pigmentosa GTPase regulator (RPGR) protein, the method comprising administering to the subject a nucleic acid comprising an adeno-associated viral vector comprising an... Ucl Business Plc

Compositions comprising ornithine and phenylacetate or phenylbutyrate for treating hepatic encephalopathy

The present invention relates to use of ornithine in the manufacture of a medicament for use in combination with at least one of phenylacetate and phenylbutyrate for preventing or treating liver decompensation or hepatic encephalopathy. The invention also relates to use of at least one of phenylacetate and phenylbutyrate in... Ucl Business Plc

Collagen biomaterials

This invention relates to methods of producing collagen biomaterials by admixing (i) a solution of monomeric collagen, (ii) a solution of polymeric collagen, (ii) cargo particles, and (iv) a non-collagen blocking polymer, to produce a collagen solution. The collagen solution is then allowed to solidify to produce a collagen hydrogel.... Ucl Business Plc

Diagnostics

The present invention relates to the detection or diagnosis of infection or inflammation in a patient. In particular, the invention provides methods that allow the detection of markers in a sample from a patient or subject, such as a blood sample, which will indicate whether the patient or subject has... Ucl Business Plc

Treatment

The present invention relates to the prevention and/or treatment of ADA-SCID, in a patient.... Ucl Business Plc

Treatment

The present invention relates to the prevention and/or treatment of lysosomal storage diseases in a patient.... Ucl Business Plc

Hif inhibitors

The invention provides inhibitors of hypoxia-inducible factors (HIF), and their use in the prevention or inhibition of diseases characterised by abnormal HIF activity or levels, such as tumour progression, and the treatment of cancer. The invention encompasses pharmaceutical compositions with a mechanism of action for blocking elevated HIF activity in... Ucl Business Plc

Truncated variant of the mammalian target for rapamycin (mtor) protein

The invention relates to mTORbeta, a splice form of mTOR, nucleic acids encoding mTOR beta, and antibodies against mTOR beta. The invention also relates to methods of producing mTOR beta and methods of screening for an agent that modulates mTOR beta expression and/or activity. The invention further relates to a... Ucl Business Plc

Rpgr-ofr15 variant gene in the treatment of retinitis pigmentosa

The present invention relates to the treatment of ocular disease, specifically retinitis pigmentosa, by gene therapy using a modified version of the RPGR-ORF15 gene.... Ucl Business Plc

Human liver scaffolds

This invention relates to methods for decellularising human liver tissue to produce human hepatic extracellular matrix (ECM) scaffolds, for example for use in therapy or disease modelling. The methods involve mechanically damaging cells in the tissue, for example by freeze thaw, and then subjecting the liver tissue to multiple cycles... Ucl Business Plc

Apparatus and testing medicaments

Apparatus for testing the solubility of a medical dosage form includes a chamber (12) for holding a solvent medium (18), in the preferred embodiment a bicarbonate based buffer system. The apparatus also includes a pH probe (66) which is connectable to a supply of carbon dioxide (32, 34), as well... Ucl Business Plc

System and computer-assisted planning of a trajectory for a surgical insertion into a skull

A system and method are provided for using a computer system to assist in planning a trajectory (960A, 960B) for a surgical insertion into a skull. The method comprises providing the computer system with a three-dimensional representation of the skull and of critical objects located within the skull, wherein the... Ucl Business Plc

Agents for use in the treatment of cardiovascular and inflammatory diseases structurally based on 4(1 h)-quinolone

said aryl, heteroaryl, cycloalkyl and heterocyclyl groups being unsubstituted or substituted with one or more substituents selected from halogen, hydroxy, C1-C4 alkyl, C1-C4 hydroxyalkyl, C1-C4 alkoxy, C1-C4 haloalkyl, C1-C4 haloalkoxy, —SOR, —SO2R, —NR′R″, —NR′(C═O)R″, —COOR, nitro and cyano substituents, wherein R, R′ and R″ are the same or different and... Ucl Business Plc

Chimeric antigen receptor

The present disclosure relates to a chimeric antigen receptor (CAR) which comprises an antigen-binding domain which selectively binds TCR beta constant region 1 (TRBC1) or TRBC2; cells; such a T cells comprising such a CAR; and the use of such cells for the treatment of a T-cell lymphoma or leukaemia... Ucl Business Plc

03/09/17 / #20170066838

Chimeric antigen receptor

Provision of a chimeric antigen receptor (CAR) comprising a disialoganglioside (GD2)-binding domain which comprises a) a heavy chain variable region (VH) having complementarity determining regions (CDRs) with the following sequences: b) a light chain variable region (VL) having CDRs with the following sequences: T cells expressing such a CAR are... Ucl Business Plc

03/02/17 / #20170056534

Detecting a therapeutic cell

The present invention relates to a method of detecting a therapeutic cell expressing a dopamine transporter (DAT) at a central nervous system (CNS) site in a subject, which comprises the administration of a DAT tracer to the subject, wherein the presence of a therapeutic cell which expresses the DAT is... Ucl Business Plc

02/23/17 / #20170049859

Factor viii sequences

There is provided a nucleic acid molecule comprising a nucleotide sequence encoding for a functional factor VIII protein, wherein the portion of the nucleotide sequence encoding for the B domain of the factor VIII protein is between 90 and 111 nucleotides in length and encodes for an amino acid sequence... Ucl Business Plc

02/16/17 / #20170042838

Treatment of fibrosis

The present invention relates an aldehyde dehydrogenase inhibitor for use in the treatment or prevention of fibrosis.... Ucl Business Plc

02/02/17 / #20170027936

Abl1 inhibitor for treating and preventing ocular neovascularisation

The present invention relates to an Abelson murine leukaemia viral oncogene homolog 1 (ABL1) inhibitor for use in the treatment of ocular neovascularisation associated with a non-cancerous condition. The invention also relates to the use of an ABL1 inhibitor as a complementary therapy with VEGF or VEGF receptor inhibitor treatment... Ucl Business Plc

01/19/17 / #20170014508

Chimeric antigen receptor (car) signalling system

The present invention relates to a chimeric antigen receptor (CAR) signalling system comprising; (i) a receptor component comprising an extracellular antigen-binding domain, a transmembrane domain and a intracellular first chemical inducer of dimerization binding domain 1 (CBD1); and (ii) an intracellular signalling component comprising a signalling domain and a second... Ucl Business Plc

01/19/17 / #20170016047

Enriching a sample of circulating cell-free nucleic acids

A method of enriching a sample of circulating cell-free DNA for DNA derived from a foetus or from a tumour includes carrying out amplification of DNA such that amplification of longer DNA molecules is discriminated against. This results in preferential amplification of foetal or tumour DNA, which can then be... Ucl Business Plc

01/19/17 / #20170016054

Detecting increase or decrease in the amount of a nucleic acid having a sequence of interest

A method of detecting copy number variations in foetal or tumour DNA within a sample of circulating cell-free DNA includes carrying out amplification of DNA such that amplification of longer DNA molecules is discriminated against. This results in preferential amplification of foetal or tumour DNA, which can then be analysed... Ucl Business Plc








ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009



###

This listing is an abstract for educational and research purposes is only meant as a recent sample of applications filed, not a comprehensive history. Freshpatents.com is not affiliated or associated with Ucl Business Plc in any way and there may be associated servicemarks. This data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Ucl Business Plc with additional patents listed. Browse our Agent directory for other possible listings. Page by FreshPatents.com

###